Published in Law and Health Weekly, September 4th, 2004
Revenue for the quarter and 6-months ended June 30, 2004, was $656,000 and $1.3 million, respectively, compared to $0 and $4.5 million for the corresponding periods in 2003. The revenue in 2004 resulted from a collaboration agreement with Genentech, which was signed at the end of 2003, while the revenue in 2003 resulted from milestone payments received from AstraZeneca plc in connection with the advancement of Cerovive (NXY-059) into Phase III clinical trials.
Research and development expenses for the second quarter and 6-month period ended June 30, 2004,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.